About this trial
To investigate the impact of abnormal glucose tolerance in hematopoietic stem cell transplantation donors on patients' post-transplant survival outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) between March 2019 and March 2024;
Donor had fasting blood glucose and/or HbA1c records
Eastern Cooperative Oncology Group (ECOG) physical fitness score of 0-2
Survived at least 12 weeks after HSCT
Disqualifiers
Active autoimmune diseases such as SLE, rheumatoid arthritis, etc.
Active cardiovascular disease such as uncontrolled arrhythmias, uncontrolled hypertension, congestive heart failure, any Grade 3 or 4 heart disease as determined by the New York Heart Association (NYHA) Functional Class, or a history of myocardial infarction in the 6 months prior to screening;
Other serious medical conditions that may limit the patient's participation in this trial (e.g., progressive infection, uncontrolled diabetes);
HIV infection, or chronic infection with hepatitis B virus (HBsAg-positive) or hepatitis C virus (anti-HCV-positive) that cannot be controlled by medications;
Trial population
Patients who were diagnosed with hematological disorders and underwent allo-HSCT
Trial design
Case-control
Retrospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Overall Survival (OS)
Patient's overall survival time since hematopoietic stem cell transplantation
Secondary outcomes
Non-relapse Mortality (NRM)
NRM after hematopoietic stem cell transplantation
Relapse-free Survival (RFS)
RFS after hematopoietic stem cell transplantation
Event-free Survival (EFS)
EFS after hematopoietic stem cell transplantation
Graft versus Host Disease (GvHD) incidence
GvHD incidence after hematopoietic stem cell transplantation
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: